Vagus nerve stimulation (VNS), a treatment that uses a small, implanted device to deliver electrical signals to the vagus nerve, was linked to fewer seizures in many children with Lennox-Gastaut syndrome (LGS), with the benefits generally becoming clearer over time, a review study…
News
Caregivers of people with Lennox-Gastaut syndrome (LGS) in focus groups most frequently cited knowledge gaps on the part of physicians as a barrier to accessing care and information. Access to care, access to information, care coordination, and transitioning from pediatric to adult care were key concerns for the group…
A checklist based on international diagnostic criteria, developed by specialists in Europe, may help doctors identify Lennox-Gastaut syndrome (LGS) earlier and support further evaluation when a diagnosis is unclear, a study showed. Because some characteristic features of LGS may emerge only…
People who meet the clinical criteria for Lennox-Gastaut syndrome (LGS) may have substantial differences in their seizure patterns, brain activity, and developmental impairment, and some severely affected patients may not meet all formal electroencephalogram (EEG) criteria used to define the condition, a study suggested. Among 105 people with clinically defined…
Questionnaires used in research to assess behavior, communication, and quality of life in people with Lennox-Gastaut syndrome (LGS) may not always capture the concerns that matter most to patients and their families, a study found. In focus groups involving caregivers, clinicians, and advocates, participants identified several areas they felt…
Fintepla (fenfluramine) can rapidly reduce seizure frequency in people with Lennox–Gastaut syndrome (LGS), with the greatest benefits typically appearing after a few months of treatment and common side effects often becoming less noticeable over time, according to a post hoc analysis of Phase 3 clinical data. “Patients, parents,…
Children with Lennox-Gastaut syndrome (LGS) experience substantial sleep disruptions, which caregivers can track at home with an electroencephalogram (EEG) headband, a study found. The HEADFIRST study showed that the Waveband device, which uses four sensors placed over the front and back of the head to record the brain’s…
Two nerve-stimulating devices, vagus nerve stimulation (VNS) and deep brain stimulation (DBS), were associated with similar reductions in seizure frequency over two years in people with Lennox-Gastaut syndrome (LGS), according to a Mayo Clinic study. At two years, however, combined DBS and ongoing VNS was associated with greater seizure…
The initial results from a large, late-stage clinical trial testing an oral seizure treatment for people with Lennox-Gastaut syndrome (LGS) and other epileptic conditions are expected by the end of this year or early next year. That’s according to new updates from Lundbeck, a pharmaceutical company specializing in treating…
Carisbamate, an experimental oral therapy for the treatment of seizures in people with Lennox-Gastaut syndrome (LGS), was generally safe and well-tolerated in children, adolescents, and adults with the disease, according to data from a Phase 1 safety study. The antiseizure medication also showed consistent pharmacokinetics, or how the…
Recent Posts
- Vagus nerve stimulation reduces seizures in kids with LGS
- My son’s love for sports helped him make the most of life with LGS
- LGS caregivers cite doctor knowledge gaps as key barrier to care
- Life took an unexpected turn after my son’s Lennox-Gastaut diagnosis
- Doctor checklist aims to facilitate earlier LGS diagnosis